Efficacy of imipenem/cilastatin in patients with severe bacterial infections
Abstract
In this study imipenem/cilastatin was used successfully to treat 21 patients with a variety of severe infections caused by Gram-positive and Gram-negative aerobic bacteria. Overall clinical cure was achieved in 18 of 21 patients. Fourteen of 16 infecting organisms were eradicated by imipenem. In spite of in-vitro susceptibility to imipenem before therapy two species of Pseudomonas (Pseudomonas aeruginosa and Ps. fluorescens) could not be eliminated in two patients. Resistance developed in the strain of Ps. aeruginosa during treatment of a patient with pneumonia for eight days. The pneumonia was considered to be clinically cured. The strain of Ps. fluorescens became resistant during therapy in a patient suffering from an acute exacerbation of severe chronic bronchitis in whom the antibiotic treatment had failed. Imipenem/cilastatin proved to be highly effective and well tolerated in this group of patients.
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.